Expression of classic cadherins type I in urothelial neoplastic progression

Rieger-Christ, Kimberly; Cain, Jason W.; Braasch, John W.; Dugan, John M.; Silverman, Mark L.; Bouyounes, Boutros T.; Libertino, John A.; Summerhayes, Ian C.

doi:10.1053/hupa.2001.21140

Cited by 60 publications

(78 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In pT 1 tumors, 80% expressed also E-cadherin. In muscle-invasive carcinomas, 39% of cases presented a concomitant expression of both E-cadherin and Ncadherin, which is in agreement with the results of RiegerChrist et al (27). On the other hand, 61% of pT 2 -T 3 tumors did not express E-cadherin.…”

Section: Discussionsupporting

confidence: 91%

“…This phenomenon has been reported in melanoma (33), breast (20), prostate (24), pancreas (34), colon (35), squamous cell carcinoma (36), but also in bladder (27). Until now, expression of N-cadherin had been observed in a small number of transitional cell carcinoma of the bladder, but no prognostic value had been recognized (27). As shown in breast cancer (20), the presence of N-cadherin/catenins complexes at the cell surface could promote the adhesion of epithelial cells to surrounding stromal cells that also express N-cadherin.…”

Section: Discussionsupporting

confidence: 55%

“…Numerous bladder cell lines have been identified to coexpress E-cadherin, Pcadherin, and N-cadherin. This cadherin expression profile has been confirmed to occur in human bladder tumors (27). In an earlier study, we reported that in spite of the decreased expression of E-cadherin in invasive bladder tumors, their cytoplasmic partners (i.e., catenins) still expressed, suggesting the presence of an other cadherin family member, such as Ncadherin (28).…”

supporting

confidence: 56%

“…Thus, a subset of tumors shows de novo expression or up-regulation of N-cadherin concomitant to their invasive stage. This phenomenon has been reported in melanoma (33), breast (20), prostate (24), pancreas (34), colon (35), squamous cell carcinoma (36), but also in bladder (27). Until now, expression of N-cadherin had been observed in a small number of transitional cell carcinoma of the bladder, but no prognostic value had been recognized (27).…”

Section: Discussionmentioning

confidence: 93%

See 3 more Smart Citations

N-Cadherin as a Novel Prognostic Marker of Progression in Superficial Urothelial Tumors

Lascombe

Clairotte

Fauconnet

et al. 2006

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Loss of intercellular adhesion and increased cell motility promote tumor cell invasion and spreading. In bladder cancer, loss or reduced E-cadherin expression has been associated with poor survival, and aberrant expression of N-cadherin has been associated with the invasive phenotype of bladder carcinoma cells. The purpose of this study was to investigate whether N-cadherin expression was associated with the bladder tumor progression. Experimental Design: E-cadherin and N-cadherin expression was evaluated by immunohistochemistry in 101tumors (pT 1 and pT 2 -T 3 ) and by reverse transcription-PCR analysis and immunohistochemistry in 28 other fresh frozen tumors (pT a , pT 1 , and pT 2 -T 3 ). Results: N-cadherin expression was absent in normal urothelium, appeared in stage pT 1 , and increased in pT 2 -pT 3 tumors. In most cases, increased N-cadherin expression in invasive tumors was associated with loss of E-cadherin expression. Progression-free survival and multivariate analyses revealed that N-cadherin expression is an independent prognostic marker for pT 1 tumor progression. Analysis of the 28 frozen tumors by immunohistochemistry and reverse transcription-PCR showed a good correlation between protein and gene expression in pT 1 and pT 2 -T 3 tumors. Interestingly, in pT a tumors, N-cadherin was not immunodetected, whereas mRNA was present in 50% of cases. Conclusion: Regulatory defects in the N-cadherin promoter, abnormalities at the translational, or protein processing levels could explain the discrepancies between protein and mRNA expression. Most importantly, this study identified N-cadherin as a novel prognostic marker of progression in superficial urothelial tumors. Clearly, N-cadherin acts in an invasive mode in bladder cancer, but whether it has a primary role in urothelial neoplastic progression has yet to be investigated.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionsupporting

confidence: 55%

supporting

confidence: 56%

Section: Discussionmentioning

confidence: 93%

See 2 more Smart Citations

N-Cadherin as a Novel Prognostic Marker of Progression in Superficial Urothelial Tumors

Lascombe

Clairotte

Fauconnet

et al. 2006

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…2,3 Reduced expression or loss of E-cadherin has been reported in various human carcinomas. [4][5][6][7][8][9][10][11][12][13][14][15] Aberrant expression of E-cadherin in human urothelial carcinoma is thought to correlate with lack of differentiation, muscle invasion and distant metastasis; however, this concept remains somewhat controversial. 12,[15][16][17][18] Greater than 90% of bladder carcinomas are usualtype urothelial carcinoma; however, a small subset of tumors are recognized as variants of urothelial carcinoma because of their distinctive histological appearance and/or poor prognosis.…”

mentioning

confidence: 99%

E-cadherin expression in plasmacytoid, signet ring cell and micropapillary variants of urothelial carcinoma: comparison with usual-type high-grade urothelial carcinoma

et al. 2011

View full text Add to dashboard Cite

Loss of E-cadherin expression has been linked to the invasive phenotypes of a variety of neoplasms, including lobular breast cancer. The expression of E-cadherin in variants of urothelial carcinoma relative to usual-type urothelial carcinoma, maximum depth of invasion and angiolymphatic invasion has not been well characterized. A total of eight cases of micropapillary urothelial carcinoma, four cases of plasmacytoid urothelial carcinoma, two cases of urothelial carcinoma with signet ring cell differentiation and two cases of urothelial carcinoma with mixed plasmacytoid and signet ring cell differentiation, all obtained from cystectomy/cystoprostatectomy cases, were identified. In all nine cases of usual-type invasive and noninvasive high-grade urothelial carcinoma were also included in the study. Immunohistochemical staining of E-cadherin was performed in all cases. Pathological parameters including depth of invasion and presence of angiolymphatic invasion were documented. Maximum depth of invasion: In micropapillary urothelial carcinoma, extravesical extension was seen in three of eight cases; muscularis propria invasion in four of eight cases; and lamina propria invasion in one of eight cases. In plasmacytoid urothelial carcinoma, extravesical extension was observed in two of four cases, and muscularis propria invasion and lamina propria invasion in one of four cases each. In urothelial carcinoma with signet ring cell differentiation, extravesical extension and muscularis propria invasion was seen in one of two cases each. In urothelial carcinoma with mixed plasmacytoid and signet ring cell differentiation, muscularis propria invasion and lamina propria invasion was observed in one of two cases each. In usual-type high-grade urothelial carcinoma, extravesical extension was seen in six of nine cases and noninvasive in three of nine cases. In angiolymphatic invasion, micropapillary urothelial carcinoma was observed in eight of eight cases; plasmacytoid urothelial carcinoma in two of four cases; urothelial carcinoma with signet ring cell differentiation in one of two cases; and urothelial carcinoma with mixed plasmacytoid and signet ring cell differentiation in one of two cases. Usual-type high-grade urothelial carcinoma was seen in six of nine cases. E-cadherin expression: All eight cases of micropapillary urothelial carcinoma were positive for E-cadherin in the micropapillary component and adjacent usual-type urothelial carcinoma. The four cases of plasmacytoid urothelial carcinoma, two cases of urothelial carcinoma with signet ring cell differentiation and two cases of urothelial carcinoma with mixed plasmacytoid and signet ring cell differentiation were all negative for E-cadherin. All nine additional cases of usual-type high-grade urothelial carcinoma were diffusely positive for E-cadherin. E-cadherin is diffusely positive in usual-type urothelial carcinoma and micropapillary urothelial carcinoma, irrespective of pathological stage and angiolymphatic invasion. Loss of E-cadherin expression may be a marker of...

show abstract

Expression of cadherin‐8 in renal cell carcinoma and fetal kidney

Blaschke

Mueller

Marković-Lipkovski

et al. 2002

Intl Journal of Cancer

View full text Add to dashboard Cite

Renal cell carcinomas (RCCs) represent 3% of all adult malignancies and are often associated with poor prognosis due to early metastasis and limited beneficial effects of current therapeutic modalities. 1 Most of these tumors originate from the proximal tubule. According to cell morphology and growth pattern, 3 main histologic tumor types can be distinguished, including clear cell carcinoma, papillary renal carcinoma and chromophobe RCC. 2 Several factors that may contribute to the process of malignant cell transformation in RCC have previously been characterized, including physical agents, chemical agents, habits, genetics (chromosomal rearrangement) and end-stage renal disease. 3 However, the pathogenic mechanisms that promote tumor progression, i.e., tumor invasion and metastasis, still have to be defined. There is accumulating evidence that cadherins may be involved in the pathogenesis of various human carcinomas by modulating celladhesive properties.The cadherin superfamily represents a group of cell-surface glycoproteins involved in cell recognition, cell signaling, cell communication, morphogenesis as well as angiogenesis and includes the groups of classic cadherins, desmosomal cadherins, protocadherins, 7TM-cadherins and T-cadherin. 4 The human classic cadherins are a group of cell-surface molecules mediating Ca 2ϩ -dependent cell adhesion by homo-or heterophilic interaction. These proteins, m.w. approximately 120 -130 kDa, are composed of an extracellular domain with 5 subdomains, each of which contains a cadherin-specific motif at the N-terminal site, a single transmembrane domain and a rather short and highly conserved cytoplasmic domain at the C-terminal site. The adhesive action of cadherins depends on the presence of Ca 2ϩ and on the function of the intracellular domain. 5 Cadherins are linked to the actin filament network through cytoplasmic interactions with catenins. These catenins regulate cadherin-mediated cell-cell adhesion. 6 In addition, these molecules may function as a downstream transcriptional activator. 7,8 More than 12 different molecules of the classic human cadherins have been identified so far by cDNA cloning. With respect to sequence homology and conservation of several amino acid residue motifs in the extracellular domain, Suzuki et al. 9 first proposed subdividing the classic human cadherins into 2 subgroups: type I (E-, N-and P-cadherins, cadherin-4) and type II (cadherins 5-15). Cadherin-8, a type II cadherin, was cloned by Tanihara et al. 10 and is characterized by strong sequence homology with the classical type I cadherins. 11 In mice, cadherin-8 expression is restricted to the developing CNS and thymus. 12,13 As has been demonstrated for type I cadherins, type II cadherins interact with ␣-and ␤-catenins. 14 Using an L-fibroblast cDNA transfection system and a long-term cell-aggregation assay, Shimoyama et al. 15 clearly demonstrated that all 8 type II cadherins exhibited cell-cell binding activity comparable to that of E-cadherin. Heterophilic interactions among the type I...

show abstract

Expression of classic cadherins type I in urothelial neoplastic progression

Cited by 60 publications

References 25 publications

N-Cadherin as a Novel Prognostic Marker of Progression in Superficial Urothelial Tumors

N-Cadherin as a Novel Prognostic Marker of Progression in Superficial Urothelial Tumors

E-cadherin expression in plasmacytoid, signet ring cell and micropapillary variants of urothelial carcinoma: comparison with usual-type high-grade urothelial carcinoma

Expression of cadherin‐8 in renal cell carcinoma and fetal kidney

Contact Info

Product

Resources

About